Health Care
Biotechnology
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Backers
1
Claris Ventures
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
2021
Founded
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers

PROSION Therapeutics is a drug development company that utilises cutting-edge technology to unlock so far undruggable targets and address…

Our mission is to improve the quality of life of patients with myocardial infarction (MI) and heart failure by providing novel…

About Us Aplagon is a clinical-stage biopharmaceutical company developing first-in-class therapeutics for a wide range of…

"We are committed to creating the future of oncology by developing innovative therapies inducing autophagy to address unmet medical needs".

Therapeutic Ultrasound-Based Solution for Vascular Care. cardiovascular disease is VTE. ¹.

Fibralign is an award-winning, Stanford-spinout company that produces novel therapeutic biomedical devices that are designed to address…
Overview
Heqet Therapeutics Heqet Therapeutics develops first-in-class non-coding RNA-based compounds to address highly unmet medical needs in acute myocardial infarction and other cardiovascular diseases.
News
SmartCella and Heqet Therapeutics enter into licensing agreement regarding the Extroducer delivery platform
SmartCella and Heqet Therapeutics enter into licensing agreement regarding the Extroducer delivery platform Press release Stockholm and Turin June 23, 2026 SmartCella Holding AB ("SmartCella")and Heqet Therapeutics Srl ("Heqet"), today announced a licensi
Read more
Report
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1

Claris Ventures 




